Danielle Fortier, Alexis Bortniker, and Sonny Allison are Partners at at Cooley LLP. This post is based on their Cooley memorandum.
The Massachusetts legislative session for 2024 has come to a close without the passage of a bill that would have targeted private equity in healthcare. Introduced in May 2024, Massachusetts House Bill (HB) 4653 proposed to expand the reach of the Health Policy Commission (HPC) by requiring notice to the HPC of any transactions involving a private equity fund investing in a provider organization, and that same bill was revised by the Massachusetts Senate in July as Senate Bill (SB) 2871.
SB 2871 made substantial changes to the House version, including making any transactions with private equity funds reviewable to assess costs and market impacts, as well as granting the HPC the ability to make adjustments to transactions. It also proposed limiting what a management services company could do for an affiliated friendly PC (professional corporation), with potentially significant impacts to the corporate structure that private equity funds historically have relied on to invest in provider organizations in states with restrictions on the ownership of healthcare practices, such as Massachusetts.
The end of the Massachusetts legislative session without the passage of a bill on this matter comes as a reprieve in a moment of escalating tension for investors in the healthcare sector.
